There is always a corner of the market where the misfits, the orphaned tickers, and the oddball ETFs end up. This is the island of misfit toys, and frankly, most of them deserve to stay there. But here's the thing: if you sift through the wreckage of ad-tech disasters and aging review sites, you occasionally find a business with actual cash flow or a technology that matters. Let's separate the wheat from the massive pile of chaff.

Let's start with the absolute disasters. Direct Digital (DRCT.US) is down over 90% over the past year. Q2 revenue plunged 23% year-over-year, and the CEO was recently seen dumping shares near the bottom. This is a sinking ship, and frankly, I don't know why anyone is still on board. Good luck with that. Then there is Hello Group (MOMO.US), the Chinese dating app parent trying to pivot to AI chatbots to save its deteriorating connection quality. They are projecting up to 2.55 billion RMB in Q2 revenue, but AI isn't a magic wand you can wave over an aging social platform.

Speaking of aging, Yelp (YELP.US) is still around, plugging along with local reviews. It's the definition of a legacy internet utility—surviving, but hardly setting the world on fire. Meanwhile, Coupang (CPNG.US) is actually doing the hard work in South Korea with its Rocket Delivery. It’s a massive logistics machine masquerading as tech, and it’s one of the few real businesses in this random assortment.

Then you have the heavily hyped health and biotech plays. Hinge Health (HNGE.US) posted an impressive USD 212.8 million in Q2 revenue (up 53%), finally showing positive net income. But it trades at a ridiculous PE multiple compared to the broader healthcare sector. Why are investors paying software multiples for digital physical therapy? Anavex Life Sciences (ASPI.US) is playing the clinical-stage biotech lottery, having just submitted its Alzheimer’s data to the FDA in late August. It’s a binary bet: either they get the nod, or the stock goes to zero.

In the energy sector, we have EOG Resources (EOG.US), a massive oil and gas player generating USD 2.8 billion in Q2 free cash flow. It’s a cash machine, though the stock has been fluctuating recently amid broader energy volatility. On the opposite end of the energy spectrum is Fervo Energy (FRVO.US). They just inked a massive 396-megawatt geothermal deal with Google, but then casually dropped that transmission bottlenecks would delay things, sending the stock crashing over 15% in a single day. You can't just announce a landmark tech partnership and then fail at basic infrastructure plumbing.

Finally, we have the ETFs designed for people who don't want to pick stocks. The Cboe Vest S&P 500 Dividend Aristocrats Target Income ETF (CPXR.US) does exactly what it says on the tin for dividend seekers, while the newly launched TappAlpha Innovation 100 ETF (TDAQ.US) is trying to milk the Nasdaq 100 with covered calls. They are fine, but they aren't going to make you rich.

My view is simple: stop buying terrible ad-tech and overvalued digital health platforms. Focus on the ones actually generating cash or building real infrastructure. The rest is just noise.

This article does not constitute investment advice.